The potent in vitro and in vivo anti-tumor activity of this compound in ER- negative breast cancer cells showed that CDRI-85/287 can serve as a lead candidate molecule for development of efficacious anti-breast cancer agent for the management of disease in patients with EGFR - overexpressing breast tumors. This evidence concerns the gene EGFR and breast cancer.